Has Howard Kerwin received payments from drug or device companies?

Yes. Drug and device makers reported $2,423 in general payments to Howard Kerwin across 158 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Howard Kerwin did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Howard Kerwin come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Howard Kerwin

Internal Medicine · Clinton Twp, MINPI 1134124209

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $782 and has fallen 95.2% since, to $37 in 2023.

$2,423in general payments, 2019–2025

Across 158 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$455
Johnson & Johnson$288
AstraZeneca$206
AbbVie$171
Novartis$133
Fresenius USA Marketing, Inc.$132
plus $1K from 22 others

What the payments were for

Food & beverage$2,423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	32	$455
Johnson & Johnson	19	$288
AstraZeneca(2 entities)	15	$206
AbbVie(2 entities)	11	$171
Novartis	9	$133
Fresenius USA Marketing, Inc.	8	$132
GSK	8	$123
Boehringer Ingelheim	7	$121
Novo Nordisk	7	$105
Takeda Pharmaceuticals U.S.A., Inc.	5	$92
Sanofi	4	$71
Mallinckrodt Enterprises LLC	4	$60
Abbott	3	$56
Otsuka America Pharmaceutical, Inc.	4	$54
Mallinckrodt Hospital Products Inc.	3	$47
Biohaven Pharmaceutical Holding Company Ltd.	2	$43
Calliditas Therapeutics US Inc.	2	$38
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$37
Bardy Diagnostics, Inc.	2	$35
Aurinia Pharma U.S., Inc.	2	$33
E.r. Squibb & Sons, L.L.C.	2	$31
Vifor Pharma, Inc.	1	$15
Ultragenyx Pharmaceutical Inc.	1	$14
Bayer	1	$14
Akebia Therapeutics Inc	1	$14
Biohaven Pharmaceuticals, Inc.	1	$12
Pfizer	1	$11
Bard Peripheral Vascular, Inc.	1	$11

How this compares

$2,423 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan →

Other internal medicine in Clinton Twp

Terry SmithAnn Arbor$2.3M
Michael ValituttoKalamazoo$1.8M
Ulka VaishampayanAnn Arbor$996K
Tina AbrahamPontiac$834K
Steven KatzmanLivonia$715K
Adam FormanSouthfield$453K
Saroj NeupaneDetroit$373K
James BazziDearborn Heights$368K
Mohamad HatahetWaterford$352K
A FendrickAnn Arbor$347K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →